Recently, Qingdao Baheal Medical INC. (Baheal Medical, 301015.SZ) announced the signing of a strategic cooperation agreement with Astrazeneca Investment (China) Co., LTD. ("Astrazeneca China").

Qingdao Baheal Medical INC. (hereinafter referred to as “Baheal Medical”, 301015.SZ) announced that it has obtained the exclusive retail channel promotion rights of Rocaltrol ® (calcitriol soft capsules)---a classic drug for the treatment of osteoporosis---in Chinese mainland. Roche pharmaceuticals China will continue to be responsible for the promotion of Rocaltrol ® in the hospital market.

On July 27, 2022, Qingdao Baheal Medical INC. (hereinafter referred to as “Baheal Medical”, 301015.SZ) announced the signing of a deepening strategic cooperation agreement with Xi’an Giant Biogene Holding Co., Ltd. (hereinafter referred to as “Giant Biogene”).

On June 17, 2022, the launch event of Zi Sheng ® which was sponsored by Shanghai Yizhong Pharma Co., Ltd. (hereafter referred to as Shanghai Yizhong, 688091.SH) and Qingdao Baheal Medical INC. (hereafter referred to as Baheal Medical, 301015.SZ) was propitiously conducted. Topics discussed included those that will open a new era for paclitaxel and a highly-effective targeted chemotherapy.

This was drawn as the starting point to jointly promote the transformation and application of successful scientific research projects, with the goal of establishing a medical and health demonstration area to drive world-class research and innovation.